FDA Panel Weighing If Human Genome's (HGSI) Drug Needs More Study
More News related to HGSI
- Human Genome Sciences (HGSI) Prices 15M Common Offering at $26.75/Share; Offering Increased from 12.5M Common
- Human Genome Sciences Announces Pricing of Public Offering of Common Stock
- Human Genome (HGSI) Raises Money As It Gears Up for Benlysta Approval
- After-Hours Movers 11/30: GES, ALTR Higher; NLST, CUTR, LTON, OVTI Lower
- Human Genome Sciences (HGSI) To Offer Up to 12.5M Shares
More News related to FDA
- Unilever (UL) Annouces Total Recall of Slim-Fast Cans
- Steris (STE) Sinks After FDA Notice on Concerns About the Steris System 1 Processor
- Watson Pharmaceuticals (WPI) Files New Drug Application with FDA for Generic Rozerem
- St. Jude (STJ) Receives U.S. FDA Approval for Penta Surgical Lead
- AstraZeneca (AZN) Gets U.S. FDA Approval for SEROQUEL XR Antidepressants
According to several Bloomberg headlines, FDA advisers are weighing if Human Genome Sciences' (Nasdaq: HGSI) drug need further studies. The panel also said that Human Genome's data "predicts response" in people.
While shares of Human Genome are trading more or less flat since the news, volume spiked sharply as the headlines hit the wires.
Related Categories
Corporate NewsFDA
Stocks Mentioned
+0.15Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
